



Oligonucleotides

Q
70L4

Editors:

Arthur M. Krieg, M.D.
C.A. Stein, M.D., Ph.D.
C. Frank Bennett, Ph.D.

EBLING LIBRARY
UNIVERSITY OF WISCONSIN
JAN 20 2006
750 Highland Avenue
Madison, WI 53706

Mary Ann Liebert, Inc.  publishers

General Information

Oligonucleotides, a quarterly journal, discusses human-made substances and their effects on gene expression at the RNA and DNA levels. It provides a forum for basic researchers in molecular and cell biology, chemical synthesis, and applied therapeutics to discuss the development of new concepts and experimental approaches to understand and modulate gene activity.

Oligonucleotides (ISSN: 1545-4576) is published 4 times a year (quarterly) by Mary Ann Liebert, Inc., 140 Huguenot Street, New Rochelle, N.Y. 10801-5215. Periodicals postage paid at New Rochelle, NY, and at additional mailing offices. **Postmaster:** Send address changes to *Oligonucleotides*, c/o Subscription Department, Mary Ann Liebert, Inc., 140 Huguenot Street, New Rochelle, N.Y. 10801-5215. Mailed in Canada under CPC CPM #40026674.

Subscriptions should be addressed to the Publisher and are payable in advance. Rates for subscriptions are for a volume of 4 issues: USA print \$563, International print \$700, USA print and online \$669, International print and online \$805, and online only (worldwide) \$526. Subscriptions begin with the first issue of the current volume. Bulk subscriptions available upon request from the Publisher. Telephone: (914) 740-2100; fax: (914) 740-2101; e-mail: info@liebertpub.com Online: www.liebertpub.com No cancellations/refunds can be honored after publication of a volume's first issue. No refunds/returns can be honored on single issue purchases.

Oligonucleotides is owned and published by Mary Ann Liebert, Inc. **Copyright © 2005** by Mary Ann Liebert, Inc. Printed in the United States of America.

Reprints, except special orders of 100 or more, are available from the authors. For permission to photocopy fewer than 25 copies for internal purposes, please request permission and pay the appropriate fee by contacting the Customer Relations Department of the Copyright Clearance Center, Inc., 22 Rosewood Drive, Danvers, MA 01923, 978-750-8400, fax: 978-750-4470. If the number of copies of an article is 25 or more, contact Reprint Sales Manager, Karen Ballen, directly at 914-740-2100, for options.

Information for Manuscript Submission is given elsewhere in the publication and on our web site: www.liebertpub.com

Business Communications should be addressed to the Publisher.

Advertising inquiries from within the United States or Canada should be addressed to Mary Ann Liebert, Inc., 140 Huguenot Street, New Rochelle, N.Y. 10801-5215; telephone: (914) 740-2100. For Europe/Outside the U.S., contact: Hilary Turnbull, imPRESS International Media Ltd., Carrington Kirk, Carrington, Midlothian EH23 4LR, UK. Telephone: 44 (0) 1875 825700; fax: 44 (0) 1875 825701; e-mail: impress@impressmedia.com All advertisements are subject to approval by the Publisher. The acceptance of advertisements does not constitute an endorsement of the product or service advertised.

Manuscripts to be considered for publication should be submitted online using the following url:

<http://www.mc.manuscriptcentral.com/oligonucleotides>

All papers, news, comments, opinions, findings, conclusions, or recommendations in *Oligonucleotides* are those of the author(s), and do not constitute opinions, findings, conclusions, or recommendations of the Journal, its Publisher, and its editorial staff.

Oligonucleotides is indexed in *MEDLINE*, *Current Contents/Life Sciences*, *EMBASE/Excerpta Medica*, *Cambridge Scientific Abstracts*, *Biotechnology Citation Index*, *Science Citation Index*, *SciSearch*, and *BIOSIS*.

Oligonucleotides is a **Journal Club** selection.

Mary Ann Liebert, Inc.  publishers

www.liebertpub.com

Oligonucleotides

The Official Journal of the Oligonucleotide Therapeutics Society, Inc.

Editors

Arthur M. Krieg, M.D.

Coley Pharmaceutical Group
93 Worcester Street
Suite 101
Wellesley, MA 02481
Tel.: (781) 431-9000, ext. 1284
Fax: (781) 431-0951
E-mail: Akrieg@coleypharma.com

C.A. Stein, M.D., Ph.D.

Department of Oncology
Albert Einstein-Montefiore Cancer
Center
Montefiore Medical Center
111 East 210 Street
Bronx, N.Y. 10467
Tel.: (718) 920-8990
Fax.: (718) 652-4027
E-mail: Cstein@montefiore.org

Reviews Editor

C. Frank Bennett, Ph.D.

Department of Molecular and
Cell Biology
ISIS Pharmaceuticals
1896 Rutherford Avenue
Carlsbad, CA 92008
Tel.: (760) 603-2336
Fax: (760) 603-4652
E-mail: Fbennett@isisph.com

Editorial Board

Sudhir Agrawal

Cambridge, MA

Sidney Altman

New Haven

Serge L. Beaucage

Bethesda

Robert D. Brown

Berkeley Heights, NJ

Marvin H. Caruthers

Boulder

Yoon S. Cho-Chung

Bethesda

Stanley Crooke

Carlsbad, CA

Nicholas M. Dean

Carlsbad, CA

Fritz Eckstein

Göttingen, Germany

Joachim Engels

Frankfurt am Main

Robert P. Erickson

Tucson

Sergio Ferrari

Modena, Italy

Michael Gait

Cambridge, UK

Wayne L. Gerlach

Canberra, Australia

Alan Gewirtz

Philadelphia

Peter M. Glazer

New Haven, CT

Martin Gleave

Vancouver, British
Columbia

Gunther Hartmann

Munich

Richard I. Hogrefe

San Diego

Jeffrey T. Holt

Denver

Mick Hope

Burnaby, British
Columbia

Jean-Louis Imbach

Montpellier, France

Burkhard Jansen

Pasadena, CA

Kuan-Teh Jeang

Bethesda

Rudolph L. Juliano

Chapel Hill

Ryszard Kole

Chapel Hill

Maria Koziolkiewicz

Lodz, Poland

Bernard Lebleu

Montpellier, France

Robert L. Letsinger

Evanston, IL

L. James Maher III

Rochester, MN

Claude Malvy

Villejuif, France

Dan Mercola

Irvine, CA

Paul S. Miller

Baltimore

Brett P. Monia

Carlsbad, CA

Ramaswamy Narayanan

Boca Raton, FL

L.M. Neckers

Rockville, MD

Paul L. Nicklin

West Sussex, UK

Eiko Ohtsuka

Sapporo, Japan

John C. Reed

La Jolla

John J. Rossi

Duarte, CA

Esther Saison-Behmoaras

Paris

Kevin Scanlon

Claremont, CA

Georg Sczakiel

Lübeck, Germany

Michael Seidman

Baltimore

Hartmut Seliger

Ülm, Germany

Barbara Ramsay Shaw

Durham

Hermona Soreq

Jerusalem

Wojciech Stec

Lodz, Poland

Martin Tabler*

Heraklion, Crete

Kazunari Taira

Tokyo

David M. Tidd

Liverpool, UK

J.-J. Toulmé

Bordeaux

Thomas Tuschl

New York, NY

Eugen Uhlmann

Langenfeld, Germany

Valentin V. Vlassov

Novosibirsk, Russia

Hermann Wagner

Munich

Daniel L. Weeks

Iowa City

Jesper Wengel

Copenhagen, Denmark

Eric Wickstrom

Philadelphia

Paul Zamecnik

Charlestown, MA

Uwe Zangemeister-Wittke

Zurich

Editor-at-Large

Florence Paillard, Ph.D.

Durango, CO

*Now deceased

Mary Ann Liebert, Inc.  publishers

Oligonucleotides

VOLUME 15

NUMBER 4

DECEMBER 2005

EDITORIAL

- A New Editor at *Oligonucleotides*** 245
A.M. Krieg

ORIGINAL PAPERS

- Evaluation of LNA-Modified DNazymes Targeting a Single Nucleotide Polymorphism in the Large Subunit of RNA Polymerase II** 246
K. Fluiter, M. Frieden, J. Vreijling, T. Koch, and F. Baas
- Potent Inhibitory Activity of Chimeric Oligonucleotides Targeting Two Different Sites of Human Telomerase** 255
E. Matthes, C. Lehmann, M. Stulich, Y. Wu, L. Dimitrova, E. Uhlmann, and M. Von Janta-Lipinski
- Strand Displacement of Double-Stranded DNA by Triplex-Forming Antiparallel Purine-Hairpins** 269
S. Coma, V. Noé, R. Eritja, and C.J. Ciudad
- Functional Analysis of 114 Exon-Internal AONs for Targeted DMD Exon Skipping: Indication for Steric Hindrance of SR Protein Binding Sites** 284
A. Aartsma-Rus, C.L. de Winter, A.A.M. Janson, W.E. Kaman, G.-J.B. van Ommen, J.T. den Dunnen, and J.C.T. van Deutekom

BRIEF COMMUNICATIONS

- New RNAi Strategy for Selective Suppression of a Mutant Allele in Polyglutamine Disease** 298
T. Kubodera, T. Yokota, K. Ishikawa, and H. Mizusawa
- Hairpin Ribozyme-Catalyzed Ligation in Water-Alcohol Solutions** 303
A.V. Vlassov, B.H. Johnston, and S.A. Kazakov

DISSERTATION SUMMARIES 310

Instructions for Authors can be found at the back of the issue and on our website at www.liebertpub.com

Mary Ann Liebert, Inc.  publishers

OLIGONUCLEOTIDES 15:284–297 (2005)
© Mary Ann Liebert, Inc.

Functional Analysis of 114 Exon-Internal AONs for Targeted DMD Exon Skipping: Indication for Steric Hindrance of SR Protein Binding Sites

ANNEMIEKE AARTSMA-RUS, CHRISTA L. DE WINTER, ANNEKE A.M. JANSON,
WENDY E. KAMAN, GERT-JAN B. VAN OMMEN, JOHAN T. DEN DUNNEN,
and JUDITH C.T. VAN DEUTEKOM

ABSTRACT

As small molecule drugs for Duchenne muscular dystrophy (DMD), antisense oligonucleotides (AONs) have been shown to restore the disrupted reading frame of DMD transcripts by inducing specific exon skipping. This allows the synthesis of largely functional dystrophin proteins and potential conversion of severe DMD into milder Becker muscular dystrophy (BMD) phenotypes. We have previously described 37 exon-internal AONs that induce skipping of 14 DMD exons in human control myotube cultures. Here, we report 77 new AONs, effectively targeting an additional 21 exons. Of the 114 AONs thus far tested, 72 (67%) were effective. AON design initially was based on a partial overlap with predicted open secondary structures in the target RNA. We have analyzed various AON and target exon parameters in retrospect. Interestingly, we observed significantly higher SF2/ASF, SC35, and SRp40 values (as predicted by ESEfinder) for effective AONs when compared with ineffective AONs. In addition, the distance to the 3' splice site was significantly smaller for effective AONs. No other significant correlations were observed. Our results suggest that effective exon-internal AONs primarily act by blocking SR binding sites (which often correspond to open structures) and that ESEfinder may be used to refine AON design for DMD and other genes.

INTRODUCTION

DUCHENNE MUSCULAR DYSTROPHY (DMD) is a severe disease that is generally caused by frame-disrupting mutations (over 60% deletions) in the *DMD* gene, which result in nonfunctional dystrophin proteins (Hoffman et al., 1987). Mutations that keep the reading frame intact give rise to internally deleted, semifunctional dystrophins and are associated with the milder Becker muscular dystrophy (BMD) (Hoffman et al., 1988; Monaco et al., 1988). This phenomenon underlies a new therapeutic approach for DMD, which is based on enlarging an out-of-frame DMD mutation into its nearest in-frame BMD counterpart. This can be achieved with antisense oligonucleotides (AONs) that induce specific exon skipping

during pre-mRNA splicing (Takeshima et al., 2001; van Deutekom et al., 2001; Wilton et al., 1999).

As splicing requires the correct identification of the branch point, the 3' and the 5' splice sites of exons by the spliceosome, these sites initially seem obvious targets for AONs to induce exon skipping. Indeed, skipping of the in-frame exon 23 that is mutated in the *mdx* mouse model was successfully induced by AONs targeting these sites (Goyenvalle et al., 2004; Lu et al., 2003, 2005; Mann et al., 2002). In addition to the consensus splice site sequences, many exons contain splicing regulatory sequences, such as exonic splicing enhancer (ESE) sequences, to facilitate the inclusion of genuine exons by the spliceosome (Cartegni et al., 2002). A subgroup of splicing factors, called the SR proteins, can bind to these

Leiden University Medical Center, Center for Human and Clinical Genetics, 2333 AL Leiden, The Netherlands.

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.